For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG HN007

Trial Overview

Official Title

Testing The Addition Of An Anti-Cancer Immune Therapy Drug (Nivolumab) To The Usual Chemo Therapy Treatment (Cisplatin Or Carboplatin With Gemcitabine) For Recurrent Or Metastatic Nasopharyngeal Cancer

Study Purpose

To compare the usual chemotherapy, cisplatin (or carboplatin) and gemcitabine alone to the usual chemotherapy plus an immune therapy drug, nivolumab.

Diagnosis

Patient has nasopharyngeal carcinoma (NPC) that has recurred or spread outside of your nasopharynx.

Eligibility

Recurrent/Metastatic Nasopharnygeal carcinoma.

Measurable disease.

No prior systemic treatment for recurrent/metastatic disease.

No prior immunotherapy

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

This study has two groups:

  • Group 1: Patients will get the immune therapy study drug called nivolumab plus cisplatin (or carboplatin) and gemcitabine.
  • Group 2: Patients will get Cisplatin (or carboplatin) and gemcitabine.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
HN007
Related Specialties